Despite the availability of effective therapies that lower low‐density lipoprotein cholesterol
(LDL‐C) levels in patients with atherosclerotic cardiovascular disease, many eligible …

Background Recent advances in telecommunications technology have raised the possibility
of telehealth intervention delivering cardiac telerehabilitation, which may provide the efficacy …

Background The 2018 US cholesterol management guideline recommends additional lipid-
lowering therapy with ezetimibe for secondary prevention in very high-risk patients with low …

Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …

Background: Patients with prior percutaneous coronary intervention (PCI) are at high
residual risk for multiple types of coronary events within and beyond the stented lesion. This …

Dyslipidemia, an imbalance of lipids and a major risk factor for cardiovascular disease, has
been associated with elevated blood and urine levels of several heavy metals. Using data …

Background and purpose Dyslipidaemia is a major risk factor for ischaemic stroke and
transient ischaemic attack (TIA). This study aimed to investigate the association between …

Objectives This study aimed to evaluate the association between increased lipoprotein
(a)[Lp (a)] and long-term outcomes in patients undergoing percutaneous coronary …

To improve cholesterol management in ASCVD patients will require an integrated approach
targeting the provider, the patient and the system. There is a need for further education of …

Background: Whether the role of plasma heat shock protein 70 (HSP70) in acute myocardial
infarction (AMI) is protective or detrimental remains debated, and the relationship between …